Governance Documents

The Board of Directors of GI Dynamics (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Management Team

Portrait

Scott Schorer, President and Chief Executive Officer

Mr. Schorer has served as a consultant to numerous boards and CEOs across a wide variety of companies in the medical device, biologics and related markets. He was Chief Executive Officer of PlasmaTech Biopharmaceuticals, Inc. from September 2014 to June 2015. From May 2010 to September 2014, Mr. Schorer ran an interim leadership and strategic consulting practice under the name of SSMC. From February 2009 to May 2010, Mr. Schorer led the turnaround effort at Systagenix Wound Management, the former Advanced Wound Care division of Johnson & Johnson, as President of the Americas. Prior to that, Mr. Schorer founded and led IST: Innovative Spinal Technologies, where he served as CEO for eight years until February 2009, during which time IST received CE Mark and FDA approvals for five products before the company was sold to Integra Spine. Prior to IST, he co-founded and was CEO of CentriMed, leading to an acquisition by Global Healthcare Exchange (“GHX”). Mr. Schorer began his medical device career as a sales representative for a surgical distributor following his career as an infantry officer in the 82nd Airborne Division as a rifle and scout platoon leader. He has led financing for over $120 million in public and private equity financings. Mr. Schorer is also a co-inventor of 6 patents, and holds Bachelor of Arts and Bachelor of Engineering degrees from Dartmouth College, where he was also captain of the men’s crew.

Portrait

Brian Callahan, Chief Compliance Officer, Executive Vice President Clinical, Regulatory and Quality Affairs and Chief Compliance Officer

Brian is an accomplished senior compliance executive with more than 25 years of experience in the medical device, pharmaceutical and biologics industries.He began his career in the United States Army as a nuclear weapons specialist and has experience working for Johnson & Johnson, Covidien and Quintiles. In 2002, Brian founded EEC & Associates, a global compliance consulting company providing clinical, regulatory and quality services to domestic and international life science companies. More recently, Brian was Executive Vice President of Clinical, Quality and Regulatory Affairs at Histogenics Corporation and was instrumental in raising $49 million to restart the NeoCart Pivotal Phase III study.

Portrait

Jim Murphy, Chief Financial Officer

Jim Murphy is an accomplished senior finance executive with more than 30 years of experience in high-growth domestic and international environments and extensive experience in the life science sector. Prior to joining GI Dynamics, he served as CFO of OXiGENE, Inc., and CFO of HemaSure, Inc. As part of a global team at Whatman Plc, he was instrumental in the sale of HemaSure assets to Whatman, including the consolidation of its worldwide operating locations from eighteen to nine.

Portrait

Karl Blohm, Ph.D., Vice President, International Operations

Karl is a seasoned strategic commercial executive and general manager with more than 20 years of medical device industry experience, combining capital equipment and medical devices in large company and small company environments. Prior to joining GI Dynamics, Karl served as partner and general manager of AB Medica France, a national medical technology distribution company he established in France. Prior to AB Medica France, Karl played a key role in leading the successful launches of innovative medical devices and technologies in his previous positions at EndoGastric Solutions, Accuray Europe and Siemens. He received a Ph.D. in physics from the University of Paris.

Board of Directors

The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.

Daniel J. Moore (Chairman)

In addition to serving as Chairman of the GI Dynamics board, Dan is also the President and CEO of the Cyberonics medical device company.

Dr. Oern Stuge

Dr. Oern Stuge, MD, MBA, brings significant experience in medical devices and specifically in type 2 diabetes and obesity. He has also lead successful clinical development programs and global commercialization efforts and has held executive and board positions with numerous medical device companies over the past 30 years. As director, he has helped lead several successful company exits, raised significant capital and launched an IPO.

Anne J. Keating

In addition to her role at GI Dynamics, Anne is also a director at REVA Medical, the Garvan Institute of Medical Research, Ardent Leisure Management, and the Goodman Group.

Timothy J. Barberich

In addition to GI Dynamics, Tim also serves on the boards of Heartware International, Inc., Tokai Pharmaceuticals, Euthymics Neuroscience, and Newcastle Holdings. He is a chairman of BioNevia Pharmaceuticals, and is the founder and former CEO of Sepracor, Inc.

Graham J. Bradley

Graham serves as a chairman for Stockland Corporation Limited, Energy Australia Holdings Limited, HSBC Australia Ltd., and Virgin Australia International Ltd., in addition to acting on the GI Dynamics board.

Juliet Thompson

Juliet Thompson has advised and raised capital for healthcare companies for more than 20 years and founded Code Securities, a healthcare investment banking firm that was sold to Nomura. In addition to GI Dyanmics, Juliet also serves as NED for Nexstim Limited, NED for Novacyt SA, and is the chair of Premier Veterinary Group Plc.

Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.